New dosing strategy for schizophrenia drug aims to cut side effects
NCT ID NCT06821945
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests different ways to start taking olanzapine, a common schizophrenia medication, to see if a slower dose increase can reduce side effects while still controlling symptoms. About 120 adults with schizophrenia will receive one of several dosing schedules or a placebo. The goal is to find a safer, effective starting plan.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Olanzapine
What this could lead to
If successful, this could lead to a safer way to start olanzapine treatment for schizophrenia, reducing side effects while still controlling symptoms.
What could go wrong
This is an early phase 2 trial with only 120 participants, so results may not apply to everyone. Different dosing schedules may not improve safety or effectiveness as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hanyang University Guri Hospital
NOT_YET_RECRUITINGGuri-si, South Korea
Contact
-
Kyungbook National university hospital
RECRUITINGDaegu, South Korea
Contact